In the Venetoclax-AML cohort, we only confirmed that the P53 mutation rate was higher in FAT1 mutant patients, while the mutation rates of DNMT3A, FLT3, and NPM1 genes showed no significant differences between FAT1 mutant and wild-type patients. This evidence concerns the gene FAT1 and acute myeloid leukemia.